首页 > 最新文献

JAMA surgery最新文献

英文 中文
Trends in the Use of Observation for Small Nonfunctional Pancreatic Neuroendocrine Tumors. 对小型无功能胰腺神经内分泌肿瘤采用观察法的趋势。
IF 15.7 1区 医学 Q1 SURGERY Pub Date : 2024-11-01 DOI: 10.1001/jamasurg.2024.2243
Samantha M Ruff, Mary Dillhoff, Susan Tsai, Timothy M Pawlik, Vineeth Sukrithan, Bhavana Konda, Jordan M Cloyd
{"title":"Trends in the Use of Observation for Small Nonfunctional Pancreatic Neuroendocrine Tumors.","authors":"Samantha M Ruff, Mary Dillhoff, Susan Tsai, Timothy M Pawlik, Vineeth Sukrithan, Bhavana Konda, Jordan M Cloyd","doi":"10.1001/jamasurg.2024.2243","DOIUrl":"10.1001/jamasurg.2024.2243","url":null,"abstract":"","PeriodicalId":14690,"journal":{"name":"JAMA surgery","volume":" ","pages":"1318-1320"},"PeriodicalIF":15.7,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11339694/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142017424","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Mechanical Bowel Preparation and Oral Antibiotics Prior to Rectal Resection-Reply. 直肠切除术前的机械肠道准备和口服抗生素--回复。
IF 15.7 1区 医学 Q1 SURGERY Pub Date : 2024-11-01 DOI: 10.1001/jamasurg.2024.2992
Laura Koskenvuo, Ville Sallinen
{"title":"Mechanical Bowel Preparation and Oral Antibiotics Prior to Rectal Resection-Reply.","authors":"Laura Koskenvuo, Ville Sallinen","doi":"10.1001/jamasurg.2024.2992","DOIUrl":"10.1001/jamasurg.2024.2992","url":null,"abstract":"","PeriodicalId":14690,"journal":{"name":"JAMA surgery","volume":" ","pages":"1327-1328"},"PeriodicalIF":15.7,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142125733","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Size Matters-Unpacking Sex-Based Disparities in Liver Transplants. 大小很重要--揭开肝脏移植中的性别差异。
IF 15.7 1区 医学 Q1 SURGERY Pub Date : 2024-11-01 DOI: 10.1001/jamasurg.2024.3506
Mohamad El Moheb, Allan Tsung
{"title":"Size Matters-Unpacking Sex-Based Disparities in Liver Transplants.","authors":"Mohamad El Moheb, Allan Tsung","doi":"10.1001/jamasurg.2024.3506","DOIUrl":"10.1001/jamasurg.2024.3506","url":null,"abstract":"","PeriodicalId":14690,"journal":{"name":"JAMA surgery","volume":" ","pages":"1299"},"PeriodicalIF":15.7,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142125738","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Elimination of the Percentile Score From the Surgical ABSITE-The Program Director Perspective. 取消外科 ABSITE 百分位数分数--项目主任的观点。
IF 15.7 1区 医学 Q1 SURGERY Pub Date : 2024-10-30 DOI: 10.1001/jamasurg.2024.4512
George A Sarosi, David A Spain, Shaneeta Johnson
{"title":"Elimination of the Percentile Score From the Surgical ABSITE-The Program Director Perspective.","authors":"George A Sarosi, David A Spain, Shaneeta Johnson","doi":"10.1001/jamasurg.2024.4512","DOIUrl":"https://doi.org/10.1001/jamasurg.2024.4512","url":null,"abstract":"","PeriodicalId":14690,"journal":{"name":"JAMA surgery","volume":" ","pages":""},"PeriodicalIF":15.7,"publicationDate":"2024-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142545518","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Elimination of the Percentile Score From the Surgical ABSITE-The Resident Perspective. 从外科 ABSITE 取消百分制评分--住院医师的视角。
IF 15.7 1区 医学 Q1 SURGERY Pub Date : 2024-10-30 DOI: 10.1001/jamasurg.2024.4509
Matthew Wheelwright, Jonathan Jenkins, Chesney Siems
{"title":"Elimination of the Percentile Score From the Surgical ABSITE-The Resident Perspective.","authors":"Matthew Wheelwright, Jonathan Jenkins, Chesney Siems","doi":"10.1001/jamasurg.2024.4509","DOIUrl":"https://doi.org/10.1001/jamasurg.2024.4509","url":null,"abstract":"","PeriodicalId":14690,"journal":{"name":"JAMA surgery","volume":" ","pages":""},"PeriodicalIF":15.7,"publicationDate":"2024-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142545519","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
New Statistical Editor-September 2024. 新任统计编辑--2024 年 9 月。
IF 15.7 1区 医学 Q1 SURGERY Pub Date : 2024-10-30 DOI: 10.1001/jamasurg.2024.4906
Melina R Kibbe
{"title":"New Statistical Editor-September 2024.","authors":"Melina R Kibbe","doi":"10.1001/jamasurg.2024.4906","DOIUrl":"https://doi.org/10.1001/jamasurg.2024.4906","url":null,"abstract":"","PeriodicalId":14690,"journal":{"name":"JAMA surgery","volume":" ","pages":""},"PeriodicalIF":15.7,"publicationDate":"2024-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142545521","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Liver Transplant Using Normothermic Machine Perfusion in Patients With High-Acuity Illness. 在重症患者中使用常温机器灌注进行肝脏移植。
IF 15.7 1区 医学 Q1 SURGERY Pub Date : 2024-10-30 DOI: 10.1001/jamasurg.2024.4101
Samer S Ebaid, Francesca A Kimelman, Koki Maeda, Christopher S Chandler, Vatche G Agopian, Douglas G Farmer, Fady M Kaldas
{"title":"Liver Transplant Using Normothermic Machine Perfusion in Patients With High-Acuity Illness.","authors":"Samer S Ebaid, Francesca A Kimelman, Koki Maeda, Christopher S Chandler, Vatche G Agopian, Douglas G Farmer, Fady M Kaldas","doi":"10.1001/jamasurg.2024.4101","DOIUrl":"10.1001/jamasurg.2024.4101","url":null,"abstract":"","PeriodicalId":14690,"journal":{"name":"JAMA surgery","volume":" ","pages":""},"PeriodicalIF":15.7,"publicationDate":"2024-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11581712/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142545520","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Diagnosis of Respiratory Sarcopenia for Stratifying Postoperative Risk in Non-Small Cell Lung Cancer. 非小细胞肺癌术后风险分层之呼吸道肌营养不良症诊断
IF 15.7 1区 医学 Q1 SURGERY Pub Date : 2024-10-30 DOI: 10.1001/jamasurg.2024.4800
Changbo Sun, Yoshifumi Hirata, Takuya Kawahara, Mitsuaki Kawashima, Masaaki Sato, Jun Nakajima, Masaki Anraku
<p><strong>Importance: </strong>Physical biomarkers for stratifying patients with lung cancer into subtypes suggestive of outcomes are underexplored.</p><p><strong>Objective: </strong>To investigate the clinical utility of respiratory sarcopenia for optimizing postoperative risk stratification in patients with non-small cell lung cancer (NSCLC).</p><p><strong>Design, setting, and participants: </strong>This retrospective cohort study reviewed consecutive patients undergoing lobectomy and mediastinal lymph node dissection for NSCLC at 2 institutions in Tokyo, Japan, between 2009 and 2018. Eligible patients underwent electronic computed tomography image analysis. Follow-up began at the date of surgery and continued until death, the last contact, or March 2022. Data analysis was performed from April 2022 to March 2023.</p><p><strong>Main outcomes and measures: </strong>Respiratory sarcopenia was identified by poor respiratory strength (peak expiratory flow rate) and was confirmed by a low pectoralis muscle index (PMI; pectoralis muscle area/body mass index). Patients with poor peak expiratory flow rate but normal PMI received a diagnosis of pre-respiratory sarcopenia. Short-term and long-term postoperative outcomes were compared among patients with a normal status, pre-respiratory sarcopenia, and respiratory sarcopenia. Group differences were analyzed using the Kruskal-Wallis test and Pearson χ2 test for continuous and categorical data, respectively. Survival differences were compared using the log-rank test. Univariable and multivariable analyses were conducted using the Cox proportional hazards model.</p><p><strong>Results: </strong>Of a total of 1016 patients, 806 (497 men [61.7%]; median [IQR] age, 69 [64-76] years) were eligible for electronic computed tomography image analysis. The median (IQR) duration of follow-up for survival was 5.2 (3.6-6.4) years. Respiratory strength was more closely correlated with PMI than pectoralis muscle radiodensity (Pearson r2, 0.58 vs 0.29). Respiratory strength and PMI declined with aging simultaneously (both P for trend < .001). Pre-respiratory sarcopenia was present in 177 patients (22.0%), and respiratory sarcopenia was present in 130 patients (16.1%). The risk of postoperative complications escalated from 82 patients (16.4%) with normal status to 39 patients (22.0%) with pre-respiratory sarcopenia to 39 patients (30.0%) with respiratory sarcopenia (P for trend < .001), as did the risk of delayed recovery after surgery (P for trend < .001). Compared with patients with normal status or pre-respiratory sarcopenia, patients with respiratory sarcopenia exhibited worse 5-year overall survival (438 patients [87.2%] vs 133 patients [72.9%] vs 85 patients [62.5%]; P for trend < .001). Multivariable analysis identified respiratory sarcopenia as a factor independently associated with increased risk of mortality (hazard ratio, 1.83; 95% CI, 1.15-2.89; P = .01) after adjustment for sex, age, smoking status, performance
重要性:用于对肺癌患者进行亚型分层的物理生物标志物尚未得到充分探索:研究呼吸道肌肉疏松对优化非小细胞肺癌(NSCLC)患者术后风险分层的临床实用性:这项回顾性队列研究回顾了 2009 年至 2018 年间在日本东京两家医疗机构接受肺叶切除术和纵隔淋巴结清扫术治疗 NSCLC 的连续患者。符合条件的患者接受了电子计算机断层图像分析。随访从手术当日开始,直至死亡、最后一次联系或 2022 年 3 月。数据分析于2022年4月至2023年3月进行:呼吸肌疏松症通过呼吸强度(呼气峰流速)差来识别,并通过胸肌指数(PMI;胸肌面积/体重指数)低来确认。呼气峰流速较低但胸肌指数正常的患者被诊断为呼吸前肌少症。研究人员比较了状态正常、呼吸肌疏松症前期和呼吸肌疏松症患者的术后短期和长期疗效。对于连续数据和分类数据,分别采用 Kruskal-Wallis 检验和 Pearson χ2 检验分析组间差异。生存率差异采用对数秩检验进行比较。采用 Cox 比例危险度模型进行单变量和多变量分析:在总共 1016 名患者中,有 806 人(497 名男性[61.7%];中位数[IQR]年龄为 69 [64-76] 岁)符合电子计算机断层图像分析条件。生存随访时间的中位数(IQR)为 5.2(3.6-6.4)年。呼吸强度与 PMI 的相关性比胸肌放射密度更密切(Pearson r2,0.58 vs 0.29)。随着年龄的增长,呼吸强度和 PMI 同时下降(趋势结论和相关性均为 P):本研究通过对呼吸肌疏松症进行筛查和分期,确定了不良预后风险较高的人群。呼吸肌疏松症的早期诊断可优化管理策略,促进 NSCLC 患者的纵向护理。
{"title":"Diagnosis of Respiratory Sarcopenia for Stratifying Postoperative Risk in Non-Small Cell Lung Cancer.","authors":"Changbo Sun, Yoshifumi Hirata, Takuya Kawahara, Mitsuaki Kawashima, Masaaki Sato, Jun Nakajima, Masaki Anraku","doi":"10.1001/jamasurg.2024.4800","DOIUrl":"10.1001/jamasurg.2024.4800","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Importance: &lt;/strong&gt;Physical biomarkers for stratifying patients with lung cancer into subtypes suggestive of outcomes are underexplored.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Objective: &lt;/strong&gt;To investigate the clinical utility of respiratory sarcopenia for optimizing postoperative risk stratification in patients with non-small cell lung cancer (NSCLC).&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Design, setting, and participants: &lt;/strong&gt;This retrospective cohort study reviewed consecutive patients undergoing lobectomy and mediastinal lymph node dissection for NSCLC at 2 institutions in Tokyo, Japan, between 2009 and 2018. Eligible patients underwent electronic computed tomography image analysis. Follow-up began at the date of surgery and continued until death, the last contact, or March 2022. Data analysis was performed from April 2022 to March 2023.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Main outcomes and measures: &lt;/strong&gt;Respiratory sarcopenia was identified by poor respiratory strength (peak expiratory flow rate) and was confirmed by a low pectoralis muscle index (PMI; pectoralis muscle area/body mass index). Patients with poor peak expiratory flow rate but normal PMI received a diagnosis of pre-respiratory sarcopenia. Short-term and long-term postoperative outcomes were compared among patients with a normal status, pre-respiratory sarcopenia, and respiratory sarcopenia. Group differences were analyzed using the Kruskal-Wallis test and Pearson χ2 test for continuous and categorical data, respectively. Survival differences were compared using the log-rank test. Univariable and multivariable analyses were conducted using the Cox proportional hazards model.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;Of a total of 1016 patients, 806 (497 men [61.7%]; median [IQR] age, 69 [64-76] years) were eligible for electronic computed tomography image analysis. The median (IQR) duration of follow-up for survival was 5.2 (3.6-6.4) years. Respiratory strength was more closely correlated with PMI than pectoralis muscle radiodensity (Pearson r2, 0.58 vs 0.29). Respiratory strength and PMI declined with aging simultaneously (both P for trend &lt; .001). Pre-respiratory sarcopenia was present in 177 patients (22.0%), and respiratory sarcopenia was present in 130 patients (16.1%). The risk of postoperative complications escalated from 82 patients (16.4%) with normal status to 39 patients (22.0%) with pre-respiratory sarcopenia to 39 patients (30.0%) with respiratory sarcopenia (P for trend &lt; .001), as did the risk of delayed recovery after surgery (P for trend &lt; .001). Compared with patients with normal status or pre-respiratory sarcopenia, patients with respiratory sarcopenia exhibited worse 5-year overall survival (438 patients [87.2%] vs 133 patients [72.9%] vs 85 patients [62.5%]; P for trend &lt; .001). Multivariable analysis identified respiratory sarcopenia as a factor independently associated with increased risk of mortality (hazard ratio, 1.83; 95% CI, 1.15-2.89; P = .01) after adjustment for sex, age, smoking status, performance ","PeriodicalId":14690,"journal":{"name":"JAMA surgery","volume":" ","pages":""},"PeriodicalIF":15.7,"publicationDate":"2024-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11581747/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142545516","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Elimination of the Percentile Score From the Surgical ABSITE-The Fellowship Director Perspective. 取消外科 ABSITE 百分位数分数--研究金主任的观点。
IF 15.7 1区 医学 Q1 SURGERY Pub Date : 2024-10-30 DOI: 10.1001/jamasurg.2024.4506
Jason T Lee
{"title":"Elimination of the Percentile Score From the Surgical ABSITE-The Fellowship Director Perspective.","authors":"Jason T Lee","doi":"10.1001/jamasurg.2024.4506","DOIUrl":"https://doi.org/10.1001/jamasurg.2024.4506","url":null,"abstract":"","PeriodicalId":14690,"journal":{"name":"JAMA surgery","volume":" ","pages":""},"PeriodicalIF":15.7,"publicationDate":"2024-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142545517","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Time Since Prior NSTEMI and Major Adverse Cardiovascular and Cerebrovascular Events After Noncardiac Surgery. 既往 NSTEMI 与非心脏手术后重大心脑血管不良事件的发生时间。
IF 15.7 1区 医学 Q1 SURGERY Pub Date : 2024-10-30 DOI: 10.1001/jamasurg.2024.4683
Laurent G Glance, Karen E Joynt Maddox, Sabu Thomas, Mark J Sorbero, Lee A Fleisher, Stewart J Lustik, Heather L Lander, Jingjing Shang, Patricia W Stone, Michael P Eaton, Marjorie S Gloff, Andrew W Dick
<p><strong>Importance: </strong>Delaying elective noncardiac surgery after a recent acute myocardial infarction is associated with better outcomes, but current American Heart Association recommendations are based on data that are more than 20 years old.</p><p><strong>Objective: </strong>To examine the association between the time since a non-ST-segment elevation myocardial infarction (NSTEMI) and the risk of postoperative major adverse cardiovascular and cerebrovascular events (MACCE).</p><p><strong>Design, setting, and participants: </strong>This cross-sectional study examined Medicare claims data between 2015 and 2020 for patients 67 years or older who had major noncardiac surgery. Data were analyzed from September 21, 2023, to February 1, 2024.</p><p><strong>Exposure: </strong>Time elapsed between a prior NSTEMI and surgery.</p><p><strong>Main outcomes and measures: </strong>MACCE (30-day mortality, in-hospital myocardial infarction, heart failure, or stroke) and all-cause 30-day mortality. Multivariable logistic regression was used to estimate the association between outcomes and time since a prior NSTEMI.</p><p><strong>Results: </strong>The sample included 5 227 473 surgeries. The mean (SD) age was 75.7 (6.6) years; 2 981 239 (57.0%) were female, and 2 246 234 (43%) were male. There were 42 278 patients (0.81%) with a previous NSTEMI. Compared with patients without a prior NSTEMI, patients with an NSTEMI within 30 days of elective surgery had higher odds of MACCE, regardless of whether they had undergone coronary revascularization (adjusted odds ratio [aOR], 2.15; 95% CI, 1.09-4.23; P = .03) or not (aOR, 2.04; 95% CI, 1.31-3.16; P = .001). The odds of postoperative MACCE leveled off after 30 days in patients who had undergone any coronary revascularization procedure (and after 90 days in patients with drug-eluting stents) and then increased after 180 days (any revascularization at 181-365 days: aOR, 1.46; 95% CI, 1.25-1.71; P < .001; patients with drug-eluting stents at 181-365 days: aOR, 1.73; 95% CI, 1.42-2.12; P < .001). The odds of MACCE did not level off for patients who did not have revascularization. Findings for all-cause 30-day mortality were similar to those for MACCE, except that the odds of mortality in patients with previous NSTEMI who had revascularization leveled off after 60 days in elective surgeries and 90 days for nonelective surgeries (elective 30-day: aOR, 2.88; 95% CI, 1.30-6.36; P = .009; elective 61- to 90-day: aOR, 1.03; 95% CI, 0.57-1.86; P = .92; nonelective 30-day: aOR, 1.91; 95% CI, 1.52-2.40; P < .001; nonelective 91- to 120-day: aOR, 1.00; 95% CI, 0.73-1.37; P = .99).</p><p><strong>Conclusions and relevance: </strong>This study found that among older patients undergoing noncardiac surgery who had revascularization, the odds of postoperative MACCE and mortality leveled off between 30 and 90 days and then increased after 180 days. The odds did not level off for patients who did not have revascularization. Delayin
重要性:在最近发生急性心肌梗死后推迟择期非心脏手术与更好的预后有关,但美国心脏协会目前的建议是基于20多年前的数据:目的:研究非 ST 段抬高型心肌梗死(NSTEMI)发生后的时间与术后主要不良心脑血管事件(MACCE)风险之间的关系:这项横断面研究检查了 2015 年至 2020 年期间 67 岁或以上接受过非心脏大手术患者的医疗保险报销数据。数据分析时间为 2023 年 9 月 21 日至 2024 年 2 月 1 日。暴露:既往 NSTEMI 与手术之间的时间间隔:MACCE(30 天死亡率、院内心肌梗死、心力衰竭或中风)和全因 30 天死亡率。采用多变量逻辑回归估计结果与既往NSTEMI发生时间之间的关系:样本包括 5 227 473 例手术。平均(标清)年龄为 75.7(6.6)岁;女性 2 981 239 人(57.0%),男性 2 246 234 人(43%)。42 278 名患者(0.81%)曾患过 NSTEMI。与既往未患 NSTEMI 的患者相比,在择期手术后 30 天内患 NSTEMI 的患者无论是否接受过冠状动脉血运重建,发生 MACCE 的几率都更高(调整后的几率比 [aOR],2.15;95% CI,1.09-4.23;P = .03)(aOR,2.04;95% CI,1.31-3.16;P = .001)。接受过任何冠状动脉血运重建手术的患者术后发生 MACCE 的几率在 30 天后趋于平稳(使用药物洗脱支架的患者在 90 天后趋于平稳),在 180 天后有所上升(181-365 天接受过任何血运重建手术:aOR,1.46;95% CI,1.25-1.71;P 结论及意义:本研究发现,在接受非心脏手术并进行血管重建的老年患者中,术后 MACCE 和死亡率的几率在 30 到 90 天之间趋于平稳,然后在 180 天后上升。而未接受血管重建手术的患者的几率并没有趋于平稳。对于接受过血管重建手术的患者来说,将择期非心脏手术推迟到 NSTEMI 后 90 天到 180 天之间可能是合理的。
{"title":"Time Since Prior NSTEMI and Major Adverse Cardiovascular and Cerebrovascular Events After Noncardiac Surgery.","authors":"Laurent G Glance, Karen E Joynt Maddox, Sabu Thomas, Mark J Sorbero, Lee A Fleisher, Stewart J Lustik, Heather L Lander, Jingjing Shang, Patricia W Stone, Michael P Eaton, Marjorie S Gloff, Andrew W Dick","doi":"10.1001/jamasurg.2024.4683","DOIUrl":"10.1001/jamasurg.2024.4683","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Importance: &lt;/strong&gt;Delaying elective noncardiac surgery after a recent acute myocardial infarction is associated with better outcomes, but current American Heart Association recommendations are based on data that are more than 20 years old.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Objective: &lt;/strong&gt;To examine the association between the time since a non-ST-segment elevation myocardial infarction (NSTEMI) and the risk of postoperative major adverse cardiovascular and cerebrovascular events (MACCE).&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Design, setting, and participants: &lt;/strong&gt;This cross-sectional study examined Medicare claims data between 2015 and 2020 for patients 67 years or older who had major noncardiac surgery. Data were analyzed from September 21, 2023, to February 1, 2024.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Exposure: &lt;/strong&gt;Time elapsed between a prior NSTEMI and surgery.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Main outcomes and measures: &lt;/strong&gt;MACCE (30-day mortality, in-hospital myocardial infarction, heart failure, or stroke) and all-cause 30-day mortality. Multivariable logistic regression was used to estimate the association between outcomes and time since a prior NSTEMI.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;The sample included 5 227 473 surgeries. The mean (SD) age was 75.7 (6.6) years; 2 981 239 (57.0%) were female, and 2 246 234 (43%) were male. There were 42 278 patients (0.81%) with a previous NSTEMI. Compared with patients without a prior NSTEMI, patients with an NSTEMI within 30 days of elective surgery had higher odds of MACCE, regardless of whether they had undergone coronary revascularization (adjusted odds ratio [aOR], 2.15; 95% CI, 1.09-4.23; P = .03) or not (aOR, 2.04; 95% CI, 1.31-3.16; P = .001). The odds of postoperative MACCE leveled off after 30 days in patients who had undergone any coronary revascularization procedure (and after 90 days in patients with drug-eluting stents) and then increased after 180 days (any revascularization at 181-365 days: aOR, 1.46; 95% CI, 1.25-1.71; P &lt; .001; patients with drug-eluting stents at 181-365 days: aOR, 1.73; 95% CI, 1.42-2.12; P &lt; .001). The odds of MACCE did not level off for patients who did not have revascularization. Findings for all-cause 30-day mortality were similar to those for MACCE, except that the odds of mortality in patients with previous NSTEMI who had revascularization leveled off after 60 days in elective surgeries and 90 days for nonelective surgeries (elective 30-day: aOR, 2.88; 95% CI, 1.30-6.36; P = .009; elective 61- to 90-day: aOR, 1.03; 95% CI, 0.57-1.86; P = .92; nonelective 30-day: aOR, 1.91; 95% CI, 1.52-2.40; P &lt; .001; nonelective 91- to 120-day: aOR, 1.00; 95% CI, 0.73-1.37; P = .99).&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusions and relevance: &lt;/strong&gt;This study found that among older patients undergoing noncardiac surgery who had revascularization, the odds of postoperative MACCE and mortality leveled off between 30 and 90 days and then increased after 180 days. The odds did not level off for patients who did not have revascularization. Delayin","PeriodicalId":14690,"journal":{"name":"JAMA surgery","volume":" ","pages":""},"PeriodicalIF":15.7,"publicationDate":"2024-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11581740/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142545523","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
JAMA surgery
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1